News and publications
Search & filter
Filter by Content Type
The many paths of MPNs: New research explores the various genetic paths of patients
Myeloproliferative neoplasms (MPNs) are rare blood cancers that often unfold slowly. Some people live with stable disease for many years, while others experience progression to myelofibrosis or acute myeloid leukemia (AML). Understanding why these paths differ is a central challenge in MPN research.
A new study, Genomic evolution and natural history of myeloproliferative neoplasms on therapy, led by researchers including Dr. Jyoti Nangalia, takes a long view of this question (Leongamornlert et al., 2026). The project tracks how the genetic makeup of MPN patients change over time and across diagnoses.
EHA & ASCO clinical trial read outs: How these impact patient quality of life
The thrill that drives researchers: Dr. Josef Prchal on ambition, competition, and the [selfish] joy of discovery
he road to scientific discovery is littered with disappointment. For researchers like Dr. Josef Prchal, MD, the moments that make the journey worthwhile are not a guaranteed outcome or incremental progress; it is the rare, intoxicating thrill of finding something no one has seen before.
Honoring Dr. Richard T Silver, MD
Few individuals have shaped the myeloproliferative neoplasm (MPN) field as steadily and thoughtfully as Dr. Richard T. Silver, MD, FACP, whose career exemplified the power of patience, independence, and long‑term scientific commitment. Over decades, he helped move the field forward by asking difficult questions early, standing by promising science long before it gained consensus, and contributing to standards of research, care, and collaboration that continue to shape how MPNs are understood today.
MPN Research Foundation (MPNRF) and Canadian MPN Research Foundation (CMPNRF) launch collaboration to improve outcomes for MPN patients
MPN Research Foundation and Canadian MPN Research Foundation are pleased to announce a new collaboration focused on improving outcomes for myeloproliferative neoplasm (MPN) patients in the U.S., Canada, and beyond. The goal of the strategic initiative is to combine expertise and resources and work together to fund and support research leading to new and better treatments and possible cures for these diseases.
The power of persistence: MPN researchers honored with Ernest Beutler Prize at ASH 2025
Inside the Orlando Convention Center, a room as vast as an airline hangar was bathed in green light from numerous two-story-high screens. Thousands of hematology researchers filled the space, waiting for a marquee lecture.